« Back
Home /
Enzastaurin

Enzastaurin

Item no.	M1704-200mg
Manufacturer	AbMole
CASRN	170364-57-5
Amount	200mg
Category	Oncology Neuroscience Neural Signaling Inhibitors & Compound Libraries Small Molecules By Organ Lung Cancer Lymphatic System Cancer
Type	Inhibitors
Specific against	other
Purity	>99%
Citations	A placebo-controlled, randomized phase II study of maintenance enzastaurin following whole brain radiation therapy in the treatment of brain metastases from lung cancer. Grønberg, et al . Lung Cancer. 2012 Aug 20. PMID: 22917813 . A Multicenter Phase II Study of Single-Agent Enzastaurin in Previously Treated Waldenstrom Macroglobulinemia. Ghobrial, et al . Clin Cancer Res. 2012 Aug 28. PMID: 22879385 . A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer. Clement-Duchene, et al . Lung Cancer. 2012 Jul 16. PMID: 22809813 . Phase I study of enzastaurin and bevacizumab in patients with advanced cancer: safety, efficacy and pharmacokinetics. Nwankwo, et al . Invest New Drugs. 2012 Jul 6. PMID: 22766773 . Combination of low doses of Enzastaurin and Lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines. Cosenza, et al . Ann Hematol. 2012 Oct,91(10):1613-22. PMID: 22623160 . Enzastaurin has anti-tumour effects in lung cancers with overexpressed JAK pathway molecules. Shimokawa, et al . Br J Cancer. 2012 Feb 28,106(5):867-75. PMID: 22333600 . A phase I study of LY317615 (enzastaurin) and temozolomide in patients with gliomas (EORTC trial 26054). Rampling, et al . Neuro Oncol. 2012 Mar,14(3):344-50. PMID: 22291006 .
ECLASS 5.1	30220300
ECLASS 6.1	30220300
ECLASS 8.0	32160605
ECLASS 9.0	32160605
ECLASS 10.0.1	32160490
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	LY317615
Similar products	Enzastaurin, LY317615
Available
Target Information	PKC
Molecular Weight	515, 61
Solubility	DMSO 20 mg/mL
Bioactivity information	Enzastaurin inhibits PKCβ, PKCα, PKCγ and PKCε with IC50's of 0.006, 0.039, 0.083 and 0.110 µM, respectively.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

M1704-200mg-safety-datasheet.pdf